http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
FDA AdCom Votes in Favor of Emergency Use Authorization for Pfizer (PFE) and BioNTech's (BNTX) Covid-19 Vaccine in Children 5 to <12 Years
-
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
-
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years
-
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
-
Pfizer (PFE) and BioNTech (BNTX) Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer (PFE) and BioNTech SE (BNTX) Report Phase 3 Data Confirming High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
-
Pfizer, BioNTech seek U.S. COVID-19 vaccine clearance for children 5-11
-
Pfizer (PFE) and BioNTech (BNTX) Confirm CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
-
Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
-
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
-
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
-
Pfizer (PFE), BioNTech (BNTX) Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
-
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
-
Pfizer (PFE) and BioNTech SE (BNTX) Announce FDA Emergency Use Authorization of COVID-19 Vaccine Booster
-
Pfizer (PFE) and BioNTech SE (BNTX) Announce FDA Emergency Use Authorization of COVID-19 Vaccine Booster
-
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
-
Pfizer (PFE), BioNTech (BNTX) in Collaboration with U.S. to Provide 500M Additional COVID-19 Vaccine Doses to Poor Nations
-
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries
-
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
-
Pfizer (PFE), BioNTech (BNTX) Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
-
Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
-
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
-
FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
-
FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
-
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
-
Pfizer (PFE) and BioNTech(BTNX) Partner With Eurofarma Laboratórios to Manufacture COVID-19 Vaccine in Latin America
-
Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
-
Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
-
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
-
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
-
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
-
Pfizer (PFE), BioNTech (BNTX) Confirm Rolling Submission of sBLA to U.S. FDA for Booster Dose of Covid-19 Vaccine
-
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
-
Pfizer (PFE), BioNTech SE (BNTX) Confirm Full U.S. FDA Approval for COVID-19 Vaccine
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
-
Pfizer (PFE), BioNTech (BNTX) Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
-
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
-
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
-
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
-
U.S. authorizes third shot of COVID-19 vaccines for the immunocompromised
-
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
-
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
-
Pfizer (PFE) And BioNTech SE (BNTX) Announces Additional 200M Vaccine Order from US Government
-
Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
-
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

